DRI Healthcare Trust (TSE:DHT.UN) Given Consensus Rating of “Moderate Buy” by Brokerages

DRI Healthcare Trust (TSE:DHT.UN) has received an average recommendation of “Moderate Buy” from the six research firms that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is C$17.94.

Several brokerages recently weighed in on DHT.UN. National Bankshares decreased their target price on DRI Healthcare Trust from C$19.50 to C$17.50 and set an “outperform” rating for the company in a research note on Thursday, February 20th. CIBC cut their price target on DRI Healthcare Trust from C$19.50 to C$18.00 and set an “outperform” rating for the company in a report on Thursday, December 12th.

DRI Healthcare Trust Trading Down 1.4 %

DHT.UN opened at C$11.39 on Wednesday. The stock has a 50-day moving average of C$11.82 and a 200-day moving average of C$12.47. DRI Healthcare Trust has a 52-week low of C$10.39 and a 52-week high of C$17.43.

DRI Healthcare Trust Company Profile

DRI Healthcare Trust is an open-ended trust that provides unitholders with differentiated exposure to the anticipated growth in the global pharmaceuticals and biotechnology markets. Its business model is focused on managing and growing a diversified portfolio of pharmaceutical royalties to deliver attractive growth in cash royalty receipts over the long term.